Not available
Quote | Fate Therapeutics Inc. (NASDAQ:FATE)
Last: | $4.705 |
---|---|
Change Percent: | 3.41% |
Open: | $4.407 |
Close: | $4.55 |
High: | $4.735 |
Low: | $4.28 |
Volume: | 1,181,447 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
News | Fate Therapeutics Inc. (NASDAQ:FATE)
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
2024-06-17 07:30:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for FATE on June 17, 2024 06:03AM ET. The previous analyst recommendation was Neutral. FATE was trading at $3.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Message Board Posts | Fate Therapeutics Inc. (NASDAQ:FATE)
Subject | By | Source | When |
---|---|---|---|
AFM28 - ADCP. | NY1972 | investorshub | 04/27/2023 4:11:19 PM |
Some CEOs won't even PR. $AFMD was a | NY1972 | investorshub | 04/27/2023 1:29:34 AM |
A letter (dated April 4th) was received saying | jondoeuk | investorshub | 04/26/2023 3:50:11 AM |
It has advantages as multiple edits can result | jondoeuk | investorshub | 04/26/2023 3:10:01 AM |
whytestocks: $FATE News Article - Fate Therapeutics to Webcast Conference Call Reporting First Quart | whytestocks | investorshangout | 04/24/2023 6:20:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
2024-06-17 07:30:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for FATE on June 17, 2024 06:03AM ET. The previous analyst recommendation was Neutral. FATE was trading at $3.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellula...